Tussin CF Dextromethorphan HBr Guaifenesin Phenylephrine HCl 20 mg/10mL; 200 mg/10mL; 10 mg/10mL Solution — NDC 70677-1187-01 package photo

Tussin CF Dextromethorphan HBr Guaifenesin Phenylephrine HCl 20 mg/10mL; 200 mg/10mL; 10 mg/10mL Solution

by Strategic Sourcing Services · 1 BOTTLE in 1 CARTON (70677-1187-1) / 237 mL in 1 BOTTLE
NDC 70677-1187-01
🏷️ FDA NDC (as labeled) 70677-1187-1 billing pads the package segment with a zero
OTC On market Non-controlled
🗂️ Data synced Sep 17, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 70677-1187-1
Product NDC 70677-1187
11-digit billing NDC 70677118701
NCPDP billing unit ML — per mL (volume)
RxCUI 1044949
UNII 9D2RTI9KYH, 495W7451VQ, 04JA59TNSJ
Application # part341
SPL Set ID e416982f-6cbb-4f48-a215-16bea8393dad
Established class (EPC) Expectorant
Physiologic effect Decreased Respiratory Secretion Viscosity; Increased Respiratory Secretions
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2023-08-09
Route ORAL
Dosage form SOLUTION
Substance DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE
GPI-14 43997303100908
GCN Seq No 000625
GCN 53090
HICL code 000216
Ingredient (HICL) Guaifen/Dextromethorphan/Pe
HIC1 code B
Therapeutic class — broad (HIC1) Respiratory System
HIC2 code B4
Therapeutic class — intermediate (HIC2) Drugs Affecting The Trachea And Bronchi (Contin.1)
HIC3 code B4R
Therapeutic class — specific (HIC3) Non-Opioid Antitussive-Decongestant-Expectorant
AHFS code 12:12.04.00
AHFS class Alpha-Adrenergic Agonists (12:12)
FDB label name FT ADULT TUSSIN CF LIQUID
FDB brand name Adult Tussin Cf
Legend status O — Over-the-counter (OTC) drug or device
Why two NDCs? The FDA registers this code as 70677-1187-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70677-1187-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Uncompetitive N-methyl-D-aspartate Receptor Antagonist class.

Pharmacologic class Uncompetitive N-methyl-D-aspartate Receptor Antagonist, Sigma-1 Agonist
Drug family (ATC) Other antidepressants, Opium alkaloids and derivatives
How it works Uncompetitive NMDA Receptor Antagonists, Sigma-1 Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerStrategic Sourcing Services
FDA applicationpart341 (OTC MONOGRAPH DRUG)
Labeler code70677
First marketedAug 2023
Product typeHuman Otc Drug
Portfolio23 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name FT ADULT TUSSIN CF LIQUID Ingredient Guaifen/Dextromethorphan/Pe
📖 About the active ingredient MedlinePlus · NLM
General information about the ingredient itself — the description of this specific product follows below.

Dextromethorphan is used to temporarily relieve cough caused by the common cold, the flu, or other conditions. Dextromethorphan will relieve a cough but will not treat the cause of the cough or speed recovery. Dextromethorphan is in a class of medications called antitussives. It works by decreasing activity in the part of the brain that causes coughing.

Read the full MedlinePlus article ↗
🧪 What is this product?

Tussin CF is an over-the-counter oral solution containing three active ingredients commonly used in cough and cold products. Dextromethorphan is a cough suppressant typically used to reduce cough reflex. Guaifenesin functions as an expectorant, traditionally used to help thin and clear mucus from the airways. Phenylephrine is a decongestant commonly used to temporarily relieve nasal congestion. This product is marketed under FDA's over-the-counter monograph rules for cough and cold medicines.

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII XF417D3PSL
    Anhydrous citric acid is a sour, crystalline powder derived from citric acid with water removed. In medicines, it acts as a buffer to control pH, adds tartness to improve taste, and helps tablets disintegrate.
  • UNII WZB9127XOA
    A synthetic red dye used to color medications and make them easier to identify. It serves as a colorant in tablets, capsules, and liquid formulations.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII L7T10EIP3A
    A cooling compound from mint plants used as a flavoring agent and to create a fresh sensation in medicines. It helps mask bitter tastes and improve how the product feels in the mouth.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII OJ245FE5EU
    Sodium benzoate is a salt derived from benzoic acid, a preservative. It's added to medicines to prevent growth of bacteria, fungi, and other microorganisms that could spoil the product.
  • UNII 8KW3E207O2
    A liquid sweetener made from sorbitol, a sugar alcohol derived from glucose. It sweetens the medicine and also acts as a humectant to help retain moisture and improve texture in liquid formulations.
  • UNII 96K6UQ3ZD4
    Sucralose is a synthetic sweetener made from sugar. It's added to medicines to improve taste without adding calories, helping make bitter or unpleasant-tasting drugs easier to take.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

9 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statesanhydrous citric acid, FD&C red no.40, glycerin, menthol, natural & artificial flavor, propylene glycol,purified water, sodium benzoate, sorbitol solution, sucralose

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.019 $4.41 / 237 ml
Medicaid paysCMS SDUD · 12 mo $0.0662 $15.69 / 237 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Dec 2025 Jan 2026 $0.019 $0.019
Flat over the last 2 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Tussin Multi Symptom Cold CF 20 mg/10mL; 200 mg/10mL; 10 mg/10mL 70000-0133-01 Cardinal 1 bottle $0.018 FDA listed save 3%
Tussin CF 20 mg/10mL; 200 mg/10mL; 10 mg/10mLthis 70677-1187-01 Strategic 1 bottle $0.019 FDA listed
Tussin Multi Symptom Cold CF Adult 20 mg/10mL; 200 mg/10mL; 10 mg/10mL 00904-6537-20 Major 1 bottle $0.021 Availability likely +12%
Tussin Multi Symptom Cold CF 20 mg/10mL; 200 mg/10mL; 10 mg/10mL 83324-0155-04 QUALITY 1 bottle $0.021 Availability likely +12%
Robitussin Peak Cold Multi-Symptom Cold 10 mg/5mL; 100 mg/5mL; 5 mg/5mL 00031-8742-14 Haleon 1 bottle FDA listed
Bactimicina Cough And Cold 10 mg/5mL; 100 mg/5mL; 5 mg/5mL 24286-1546-04 DLC 1 bottle FDA listed
Tukol Honey Children Cough and Congestion 5 mg/2.5mL; 50 mg/2.5mL; 2.5 mg/2.5mL 50066-0301-04 Genomma 1 bottle FDA listed
Tukol Multi Symptom Cold 10 mg/5mL; 100 mg/5mL; 5 mg/5mL 50066-0504-24 Genomma 118 ml FDA listed
Tukol Cough and Congestion 10 mg/5mL; 100 mg/5mL; 5 mg/5mL 50066-0510-04 Genomma 1 bottle FDA listed
Tukol X-Pecto Miel Multi Symptom Cold 10 mg/5mL; 100 mg/5mL; 5 mg/5mL 50066-0533-24 Genomma 118 ml FDA listed
Tukol Cough And Cold Honey Flavor 100 mg/5mL; 5 mg/5mL; 10 mg/5mL 50066-0534-04 Genomma 1 bottle FDA listed
GoodSense Tussin CF Multi-Symptom Cold, Raspberry 5 mg/5mL; 10 mg/5mL; 100 mg/5mL 50804-0256-04 Geiss, 118 ml FDA listed
Desgen Dm 10 mg/5mL; 100 mg/5mL; 5 mg/5mL 52083-0646-16 Kramer 474 ml FDA listed
Mucosan Multi-Symptom Cherry 10 mg/5mL; 5 mg/5mL; 100 mg/5mL 53145-0693-04 Menper 1 bottle FDA listed
Mucosan Multi-Symptom Honey 10 mg/5mL; 100 mg/5mL; 5 mg/5mL 53145-0695-04 Menper 1 bottle FDA listed
Tussin CF Multi-Symptom Cold 10 mg/5mL; 100 mg/5mL; 5 mg/5mL 53942-0504-26 DeMoulas 237 ml FDA listed
Tussin CF 10 mg/5mL; 100 mg/5mL; 5 mg/5mL 53943-0504-26 Discount 237 ml FDA listed
Multi-Symptom Cold 20 mg/10mL; 200 mg/10mL; 10 mg/10mL 55319-0201-36 Family 1 bottle FDA listed
Broncomiel Adults 200 mg/10mL; 10 mg/10mL; 20 mg/10mL 55758-0512-09 Pharmadel 1 bottle FDA listed
Rompe Pecho CF 10 mg/5mL; 100 mg/5mL; 5 mg/5mL 58593-0235-04 Efficient 118 ml Discontinued
Tussin Multi Symptom Cold CF 20 mg/10mL; 200 mg/10mL; 10 mg/10mL 63941-0382-04 Best 1 bottle FDA listed
Tussin CF 20 mg/10mL; 200 mg/10mL; 10 mg/10mL 63941-0823-04 Best 1 bottle FDA listed
Tussin CF Non Drowsy Multi Symptom 20 mg/10mL; 200 mg/10mL; 10 mg/10mL 67091-0266-18 WinCo 1 bottle FDA listed
Tussin CF 20 mg/10mL; 200 mg/10mL; 10 mg/10mL 67091-0470-04 WinCo 1 bottle FDA listed
Tussin CF 20 mg/10mL; 200 mg/10mL; 10 mg/10mL 67091-0691-04 WinCo 1 bottle FDA listed
Tussin Cf 10 mg/5mL; 100 mg/5mL; 5 mg/5mL 76281-0504-24 AptaPharma 118 ml FDA listed
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2023
On the market since
Aug 2023
📍
2026
Currently FDA-listed
3 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 70677-1187-01, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
15
Units reimbursed last 4 qtrs
3.5K
Gross reimbursed last 4 qtrs
$232.96
Avg / prescription
$15.53
Avg / unit
$0.0662
Latest quarter Q4 2025
15Rx
Medicaid pays / mL
$0.0662
gross reimbursed
vs
NADAC / mL
$0.0186
acquisition cost
=
Spread
+$0.0476
+256% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
100% FFS
Fee-for-service · 15 Rx Managed care · 0 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: no data reported NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: 3,520 units · 9.0 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
9.09.0
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 California 9.0 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Tussin CF (this brand).

Top reported reactions

Pain8
Abdominal Pain Upper6
Cough6
Dyspnoea6
Headache6
Death5
Dizziness5

Reporter sex

65 reports

Serious outcomes

Death6
Disabling5
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 8 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
70677-1187-01 You're viewing this 1 BOTTLE in 1 CARTON (70677-1187-1) / 237 mL in 1 BOTTLE 2023-08-09 Active

📄 FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 35 words

Uses ■ helps loosen phlegm (mucus) and thin bronchial secretions to drain bronchial tubes ■ temporarily relieves these symptoms occurring with a cold: • nasal congestion • cough due to minor throat and bronchial irritation.

⏱️ Dosage and Administration 69 words

Directions ■ mL = milliliter ■ do not take more than 6 doses in any 24 hour period ■ this adult strength product is not intended for use in children under 12 years of age ■ measure only with dosing cup provided ■ keep dosing cup with product AGE DOSE Adults and children 12 years and over 10 mL every 4 hours Children under 12 years do not use

⚠️ Warnings 57 words

Warnings Do not use ■ if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.

🧪 Active Ingredient 21 words

Active ingredients (in each 10 mL) Dextromethorphan HBrDextromethorphan HBr, USP 20 mg Guaifenesin, USP 200 mg Phenylephrine HCI, USP 10 mg

🧪 Inactive Ingredients 22 words

Inactive ingredients anhydrous citric acid, FD&C red no.40, glycerin, menthol, natural & artificial flavor, propylene glycol,purified water, sodium benzoate, sorbitol solution, sucralose

🎯 Purpose 6 words

Purposes Cough suppressant Expectorant Nasal decongestant

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.